With respect to the finding that overexpression of most TRIM members tightly correlated with low overall patient survival rates and disease recurrence, TRIMs represent attractive therapeutic targets and novel tumor markers for early diagnosis and risk assessment as well as therapy of CRC. The gene discussed is TRAT1; the disease is neoplasm.